BRIEF-Vistagen Announces Topline Results From Palisade-3 Phase 3 Study

Reuters12-17

Dec 17 (Reuters) - VistaGen Therapeutics Inc VTGN.O:

VISTAGEN ANNOUNCES TOPLINE RESULTS FROM PALISADE-3 PHASE 3 PUBLIC SPEAKING CHALLENGE STUDY OF FASEDIENOL FOR THE ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER
VISTAGEN THERAPEUTICS INC - STUDY DID NOT SHOW SIGNIFICANT IMPROVEMENT IN ANXIETY REDUCTION
VISTAGEN THERAPEUTICS INC - FAVORABLE SAFETY DATA OF FASEDIENOL CONSISTENT WITH PREVIOUS TRIALS
VISTAGEN THERAPEUTICS INC - CASH PRESERVATION MEASURES EXPECTED TO PROVIDE RUNWAY INTO 2027

Source text: ID:nBwbsFCZWa

Further company coverage: VTGN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592913314?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 21:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592913314","market":"us","top_or_hot":-1,"title":"BRIEF-Vistagen Announces Topline Results From Palisade-3 Phase 3 Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Vistagen Announces Topline Results From Palisade-3 Phase 3 Study</title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span>VistaGen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>VTGN.O</span>:</p><ul><li><p>VISTAGEN ANNOUNCES TOPLINE RESULTS FROM PALISADE-3 PHASE 3 PUBLIC SPEAKING CHALLENGE STUDY OF FASEDIENOL FOR THE ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER</p></li><li><p>VISTAGEN THERAPEUTICS INC - STUDY DID NOT SHOW SIGNIFICANT IMPROVEMENT IN ANXIETY REDUCTION</p></li><li><p>VISTAGEN THERAPEUTICS INC - FAVORABLE SAFETY DATA OF FASEDIENOL CONSISTENT WITH PREVIOUS TRIALS</p></li><li><p>VISTAGEN THERAPEUTICS INC - CASH PRESERVATION MEASURES EXPECTED TO PROVIDE RUNWAY INTO 2027</p></li></ul><p>Source text: <span>ID:nBwbsFCZWa</span></p><p>Further company coverage: <span>VTGN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Vistagen Announces Topline Results From Palisade-3 Phase 3 Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Vistagen Announces Topline Results From Palisade-3 Phase 3 Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-17 21:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Vistagen Announces Topline Results From Palisade-3 Phase 3 Study</title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span>VistaGen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>VTGN.O</span>:</p><ul><li><p>VISTAGEN ANNOUNCES TOPLINE RESULTS FROM PALISADE-3 PHASE 3 PUBLIC SPEAKING CHALLENGE STUDY OF FASEDIENOL FOR THE ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER</p></li><li><p>VISTAGEN THERAPEUTICS INC - STUDY DID NOT SHOW SIGNIFICANT IMPROVEMENT IN ANXIETY REDUCTION</p></li><li><p>VISTAGEN THERAPEUTICS INC - FAVORABLE SAFETY DATA OF FASEDIENOL CONSISTENT WITH PREVIOUS TRIALS</p></li><li><p>VISTAGEN THERAPEUTICS INC - CASH PRESERVATION MEASURES EXPECTED TO PROVIDE RUNWAY INTO 2027</p></li></ul><p>Source text: <span>ID:nBwbsFCZWa</span></p><p>Further company coverage: <span>VTGN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VTGN","symbol_name":"VistaGen Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA4ZWW0K:1","article_id":"2592913314","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592913314","pubTimestamp":1765979408,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Vistagen Announces Topline Results From Palisade-3 Phase 3 StudyDec 17 (Reuters) - VistaGen Therapeutics Inc VTGN.O:VISTAGEN ANNOUNCES TOPLINE RESULTS FROM PALISADE-3 PHASE 3 PUBLIC SPEAKING CHA","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VTGN":"VistaGen Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"简介-Vistagen公布PALISADE-3 3期研究的主要结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTGN":0.9},"content_text":"BRIEF-Vistagen Announces Topline Results From Palisade-3 Phase 3 StudyDec 17 (Reuters) - VistaGen Therapeutics Inc VTGN.O:VISTAGEN ANNOUNCES TOPLINE RESULTS FROM PALISADE-3 PHASE 3 PUBLIC SPEAKING CHALLENGE STUDY OF FASEDIENOL FOR THE ACUTE TREATMENT OF SOCIAL ANXIETY DISORDERVISTAGEN THERAPEUTICS INC - STUDY DID NOT SHOW SIGNIFICANT IMPROVEMENT IN ANXIETY REDUCTIONVISTAGEN THERAPEUTICS INC - FAVORABLE SAFETY DATA OF FASEDIENOL CONSISTENT WITH PREVIOUS TRIALSVISTAGEN THERAPEUTICS INC - CASH PRESERVATION MEASURES EXPECTED TO PROVIDE RUNWAY INTO 2027Source text: ID:nBwbsFCZWaFurther company coverage: VTGN.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592913314","isCrawlerRequest":true}